Agoracom

-going to have to wait to see the stocks reaction tomorrow, might not be what we were waiting for. "While the trial did not meet its primary endpoints, subgroup analyses of patients with moderate to severe pain and more impaired physical function at baseline showed positive trends in patients treated with Indaflex(TM) as compared to patients treated with either placebo or vehicle. Indaflex(TM) was demonstrated to be safe and well tolerated." -On the other hand "The results of this initial clinical trial provide supportive evidence for the efficacy and safety of Indaflex(TM)" -Someone more familiar with trials like this may have to shed some light on the implication of the results. http://www.marketwatch.com/news/story/alpharx-proprius-pharmaceuticals-announce-top/story.aspx?guid=%7B9DB0B2A1%2D26F8%2D418E%2DB761%2D2C251999978A%7D&dist=TQP_Mod_pressN